<?xml version="1.0" encoding="UTF-8"?>
<p>Ki67 is a well‐known proliferation marker used for the independent evaluation of the prediction of cancer progression.
 <xref rid="cam43799-bib-0021" ref-type="ref">
  <sup>21</sup>
 </xref> Oncoprotein E7 of HPV inactivates the function of pRb, leading to P16ink4a accumulation.
 <xref rid="cam43799-bib-0022" ref-type="ref">
  <sup>22</sup>
 </xref> P16ink4a/Ki67 immunocytochemistry can achieve a sensitivity of 86% for LSIL and 88% for HSIL.
 <xref rid="cam43799-bib-0023" ref-type="ref">
  <sup>23</sup>
 </xref> Accordingly, we used Ki67 as a positive control for histopathological staging in our study and compared it with our novel biomarkers, but the obvious insufficiency of Ki67 is that it cannot recognize the different histological stages of cervical cancer. Therefore, more effective and affordable screening methods are needed. Protein‐based biomarkers, such as SCC‐Ag,
 <xref rid="cam43799-bib-0006" ref-type="ref">
  <sup>6</sup>
 </xref> p16,
 <xref rid="cam43799-bib-0024" ref-type="ref">
  <sup>24</sup>
 </xref> CEA,
 <xref rid="cam43799-bib-0025" ref-type="ref">
  <sup>25</sup>
 </xref> CYFRA,
 <xref rid="cam43799-bib-0026" ref-type="ref">
  <sup>26</sup>
 </xref> sCD44, MMP‐9,
 <xref rid="cam43799-bib-0027" ref-type="ref">
  <sup>27</sup>
 </xref> GINS2,
 <xref rid="cam43799-bib-0028" ref-type="ref">
  <sup>28</sup>
 </xref> HBXIP 
 <xref rid="cam43799-bib-0029" ref-type="ref">
  <sup>29</sup>
 </xref> and Pin1 
 <xref rid="cam43799-bib-0030" ref-type="ref">
  <sup>30</sup>
 </xref> had reported, are relevant to cervical cancer. Unfortunately, most of them are applied for prognosis or efficacy evaluation, whereas specific biomarkers for various histological stages of cervical cancer for early diagnosis and treatment remain unknown.
</p>
